What is the national unified selling price of Ensifentrine?

Ohtuvayre (Ensifentrine)-Ensefentine Inhalation Suspension Solution is a dual phosphodiesterase inhibitor (PDE3/PDE4 inhibitor) with an innovative mechanism. It is mainly used to treat chronic obstructive pulmonary disease (COPD). At present, the drug has not been officially launched in mainland China, nor has it been included in the medical insurance catalog, so there is no unified national price.

According to overseas market data, the U.S. version of the original version of Ensefentin is sold in the form of an inhalation atomizer, with a specification of 3mg/2.5mL (60 doses). The price of a single box is about RMB 40,000, but the actual selling price will be affected by multiple factors such as dollar exchange rate fluctuations, transportation, and agency fees. The drug is temporarily unavailable through hospital prescriptions in China. Patients who need to use it usually need to import it through cross-border drug purchase or medical intermediaries. During the process, special attention must be paid to the formality and legality of the drug source.

Judging from overseas usage, exefentine is mainly used as a maintenance treatment drug to improve lung function and symptom control in patients with COPD, especially for those patients who have poor response to traditional bronchodilators or glucocorticoids. There are currently no generic drugs on the market, so prices remain high, which also shows that they are still in the early stages of the new drug life cycle. For patients who plan to use this drug, in addition to paying attention to the price, they should also focus on evaluating their own lung condition, drug adaptability and long-term affordability. It is recommended to consult a professional respiratory doctor or an institution with cross-border drug experience for medication guidance in advance.

In the future, if exefantine is officially approved for marketing in China, its price is expected to be adjusted based on medical insurance negotiations, market access strategies and supply chain costs, and may drop significantly. Therefore, you can pay attention to the dynamics of the National Food and Drug Administration (NMPA) and the medical insurance catalog to keep abreast of relevant policy progress.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html